In a hospital ward in Bunia, a nurse pulls on a second layer of gloves before she takes a blood sample, aware that the virus she is testing for has already reached two hospitals in Europe this year. One patient was evacuated to Germany in May. In June, another was verified in France. Neither had set foot in Britain, but there is no reason the next one will show the same courtesy. The outbreak now unfolding in the Democratic Republic of the Congo has become the second-largest Ebola epidemic ever recorded, with more than 3,800 cases and over 1,700 deaths reported by the government in Kinshasa, and a fatality rate that has climbed steadily from roughly a quarter of cases in mid-June to close to half of them now. The strain responsible, Bundibugyo, has no licensed vaccine and no approved treatment. That single fact ought to concentrate minds in London rather more than it appears to.

Britain likes to describe its pandemic posture in terms of a doctrine: prevent, detect, respond. The phrase survived the public inquiries into COVID-19 more or less intact, repeated in strategy documents and select committee evidence as proof that lessons had been absorbed. What has not survived so well is the funding that gives the doctrine any content. Overseas development spending, much of which underwrites the surveillance networks, laboratory capacity and contact-tracing infrastructure that catch outbreaks before they cross borders, has been reduced substantially in successive fiscal settlements. The Congo response itself has already been slowed by an equivalent contraction in American funding, with cuts to USAID support for the country's health system tracked in the hundreds of millions of dollars. When aid budgets fall, the institutions meant to detect the next Bunia before it becomes the next Kinshasa are the first to feel it. Prevention, in other words, is precisely the part of the doctrine that gets cut first, because its costs are visible now and its benefits are invisible until the year they are not.

The detection and response arms of that doctrine sit with UKHSA and with the NHS's small network of high consequence infectious disease units, of which the Royal Free's isolation facility is the best known. There is no immediate cause to doubt that these units would operate successfully again, as they did during the West Africa outbreak ten years ago and throughout later flare-ups. But capacity of this kind is not maintained by good intentions. It depends on specialist staff rotations, on regular exercising of protocols that are otherwise rarely used, and on a level of surge readiness that competes for funding against every other pressure on NHS budgets, from elective waiting lists to emergency department overcrowding. A system already absorbing repeated efficiency demands has limited appetite for maintaining expensive contingency capability against a risk that, until an aeroplane lands with a symptomatic passenger, feels abstract.

There is a narrower opportunity buried in this outbreak too. In the years immediately following COVID-19, the UK's vaccine research base was established to address this kind of issue. The lack of a licensed vaccine or treatment for the Bundibugyo strain is a true scientific gap, not a regulatory one. That infrastructure, assembled around Oxford's Jenner Institute and the now largely dismantled Vaccine Taskforce, was constructed for exactly this purpose: rapid platform development against a pathogen family already partially understood. Whether that capability still exists in usable form, after several years of drawdown, is a fair question for the Department of Health and Social Care and for the life sciences sector alike.

None of this argues that Britain faces an imminent Ebola crisis of its own. It argues something narrower and, in some ways, more uncomfortable: that the country has a doctrine it can recite fluently and a funding settlement that no longer matches it. The gap between the two is not visible in a select committee hearing. It becomes visible, usually with very little warning, on the day a nurse somewhere in the NHS has to remember how to use it.